[go: up one dir, main page]

DE60112102D1 - Kombination aus einem no-donor und einem antioxidans zur behanndlung sexueller störungen - Google Patents

Kombination aus einem no-donor und einem antioxidans zur behanndlung sexueller störungen

Info

Publication number
DE60112102D1
DE60112102D1 DE60112102T DE60112102T DE60112102D1 DE 60112102 D1 DE60112102 D1 DE 60112102D1 DE 60112102 T DE60112102 T DE 60112102T DE 60112102 T DE60112102 T DE 60112102T DE 60112102 D1 DE60112102 D1 DE 60112102D1
Authority
DE
Germany
Prior art keywords
donor
antioxidan
management
combination
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60112102T
Other languages
English (en)
Other versions
DE60112102T2 (de
Inventor
S Sacks
Dyke Knox Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24622335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60112102(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of DE60112102D1 publication Critical patent/DE60112102D1/de
Application granted granted Critical
Publication of DE60112102T2 publication Critical patent/DE60112102T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60112102T 2000-09-01 2001-08-29 Kombination aus einem no-donor und einem antioxidans zur behandlung sexueller störungen Expired - Lifetime DE60112102T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/653,794 US7128930B1 (en) 2000-09-01 2000-09-01 Compositions and methods for treating sexual dysfunction
US653794 2000-09-01
PCT/US2001/026817 WO2002019999A2 (en) 2000-09-01 2001-08-29 Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant

Publications (2)

Publication Number Publication Date
DE60112102D1 true DE60112102D1 (de) 2005-08-25
DE60112102T2 DE60112102T2 (de) 2006-05-24

Family

ID=24622335

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60112102T Expired - Lifetime DE60112102T2 (de) 2000-09-01 2001-08-29 Kombination aus einem no-donor und einem antioxidans zur behandlung sexueller störungen

Country Status (10)

Country Link
US (1) US7128930B1 (de)
EP (1) EP1317309B1 (de)
JP (1) JP2004511443A (de)
AT (1) ATE299740T1 (de)
AU (1) AU2001288460A1 (de)
CA (1) CA2419404C (de)
DE (1) DE60112102T2 (de)
ES (1) ES2242768T3 (de)
MX (1) MXPA03001798A (de)
WO (1) WO2002019999A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1022860C2 (nl) * 2003-03-06 2004-09-07 Concepto Worldwide Ltd Inrichting voor het stimuleren van het vrouwelijk geslachtsorgaan, verpakking en doseerorgaan.
ATE418976T1 (de) * 2005-08-04 2009-01-15 Extarma Ag Flüssige zusammensetzung enthaltend arginine und alpha-liponsäure zur verbesserung der sexuellen funktion
US20090197892A1 (en) * 2007-08-21 2009-08-06 Nawaz Ahmad Anhydrous compositions useful for attaining enhanced sexual wellness
US20130210867A1 (en) * 2010-04-15 2013-08-15 Life Science Enhancement Corporation Methods and compositions for enhancing female sexual arousal and treating female sexual dysfunction
JP2013049670A (ja) * 2011-08-04 2013-03-14 Fancl Corp アスコルビン酸製剤
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
DE102013018565A1 (de) 2013-10-28 2015-04-30 Gmbu E.V., Fachsektion Dresden Körperpflegemittel und dessen Verwendung
ITMI20132049A1 (it) 2013-12-09 2015-06-10 Multichem S A S Di Gabriele Segall A Composizioni e metodo per la stimolazione della risposta sessuale femminile e maschile
WO2018094377A1 (en) * 2016-11-21 2018-05-24 REV Pharmaceuticals LLC Sexual health enhancement composition

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242391A (en) 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
GB9214247D0 (en) 1992-07-04 1992-08-19 Stephan Peter M Composition for use as a food or food supplement
EP0696919B1 (de) 1993-04-05 2002-01-30 Competitive Technologies, Inc. Diagnose und behandlung von erektilen funktionsstörungen
US5439938A (en) 1993-04-07 1995-08-08 The Johns Hopkins University Treatments for male sexual dysfunction
ES2091724B1 (es) 1995-04-07 1997-06-01 Ropero Wermenlinger Luis Nueva locion potenciadora de la capacidad sexual en el hombre, procedimiento para su preparacion y sus aplicaciones.
US5595753A (en) * 1995-04-14 1997-01-21 President And Fellows Of Harvard College Topical formulations and methods for treating hemorrhoidal pain and sphincter and smooth muscle spasm in the gastrointestinal tract
US5645839A (en) * 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
US6207713B1 (en) * 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US6071272A (en) 1997-10-28 2000-06-06 Hoffman; Alan S. Method for treating erectile dysfunctionality
US6180133B1 (en) * 1997-11-25 2001-01-30 Watson Pharmaceuticals, Inc. Antioxidant composition for topical/transdermal prevention and treatment of wrinkles
WO1999051252A1 (en) 1998-04-03 1999-10-14 The Daily Wellness Company Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
US6031002A (en) * 1998-05-01 2000-02-29 Michael Ebert Method for enhancing female sexual response and a composition therefor
WO2000000212A1 (en) 1998-06-26 2000-01-06 Nutracorp Scientific, Inc. Promoting nitric oxide and cyclic gmp activity
US6007824A (en) * 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction
US6476037B1 (en) * 2000-03-23 2002-11-05 The Regents Of The University Of California L-arginine and phosphodiesterase (PDE) inhibitor synergism
RU2163805C1 (ru) 2000-03-29 2001-03-10 Закрытое Акционерное Общество Научно-Производственный Центр "Борщаговский Химико-Фармацевтический Завод" Средство для лечения расстройств половой функции у мужчин

Also Published As

Publication number Publication date
CA2419404A1 (en) 2002-03-14
EP1317309B1 (de) 2005-07-20
EP1317309A2 (de) 2003-06-11
CA2419404C (en) 2012-10-16
DE60112102T2 (de) 2006-05-24
US7128930B1 (en) 2006-10-31
WO2002019999A2 (en) 2002-03-14
MXPA03001798A (es) 2004-11-01
ATE299740T1 (de) 2005-08-15
WO2002019999A3 (en) 2003-03-27
ES2242768T3 (es) 2005-11-16
JP2004511443A (ja) 2004-04-15
AU2001288460A1 (en) 2002-03-22

Similar Documents

Publication Publication Date Title
DE60112102D1 (de) Kombination aus einem no-donor und einem antioxidans zur behanndlung sexueller störungen
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
ATE323473T1 (de) Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon
ATE347879T1 (de) Transdermale pharmazeutische zusammensetzung zur wirkstoffverabreichung
IL138979A0 (en) Use of cannabinoids as anti-inflammatory agents
AP1666A (en) Quinolinone derivatives as tyrosine kinase inhibitors.
BR0313575C1 (pt) Método para melhorar a eficácia e/ou transporte transdermal de nutrientes e nutricêuticos topicamente administrados, veìculo para ser utilizado da administração tópica ou transdermal de nutrientes ou nutricêuticos, composição nutricêutica e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons junto com outros excipientes
MY119403A (en) Novel compounds with analgesic effect.
HN2004000232A (es) " derivados de pirrolo(3,4-c) pirazol activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden."
NO20006560D0 (no) Apomorfinholdige doseringsformer for forbedring av erektil dysfunksjon hos menn
AR011583A1 (es) Conjunto de medicamentos para tratar el cancer
MXPA04000654A (es) Terapia dermica usando derivados de fosfato de agente de transferencia de electrones.
SE9802208D0 (sv) Novel compounds
ATE383863T1 (de) Kombinationschemotherapie
DE60320034D1 (de) Behandlung von mastitis mit einer kombination aus prednisolon und cephalosporin
KR960704561A (ko) 바이러스성 유발 종양의 예방과 치료용 조성물
KR920019350A (ko) 자기면역질환요법을 위한 약제조성물
TW200503709A (en) Itching treating agent containing piperidine derivative as active ingredient
GEP20043231B (en) Resorcinol Composition
SE9904132D0 (sv) Pharmaceutical composition for treatment of diarrhea
AU2001258859A1 (en) Pralmorelin-containing nasal drop preparations
US20040023937A1 (en) Anti-cancer formulation
DE60130253D1 (de) Zusammensetzungen zur verhinderung der adhäsion
WO2000067699A3 (en) Pharmaceutical compositions for treating malaria
AR039604A1 (es) Utilizacion de una sal de acido l-ascorbico para la preparacion de una composicion farmaceutica, para uso oftalmico topico, capaz de mejorar el nivel de acido l-ascorbico en el ojo

Legal Events

Date Code Title Description
8364 No opposition during term of opposition